This article is more than 5 years old. Information may no longer be current.

Ganfort granted EU approval

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — A combination treatment for glaucoma has been granted regulatory approval from European authorities, the drug’s marketer said in a press release.

Allergan’s Ganfort, a combination of bimatoprost and timolol, is indicated for the reduction of IOP in patients with open-angle glaucoma of ocular hypertension, who are insufficiently responsive to topical beta blockers or prostaglandin analogues, Allergan said.

The fixed combination of bimatoprost 0.03% and timolol 0.5%, the glaucoma medication “offers powerful IOP-lowering efficacy comparable to the free combination of these two agents, and greater efficacy than monotherapy with either agent alone,” Allergan said in the release.

Ganfort has been approved for once-daily dosing, which Allergan said will help improve patient compliance. According to the release, Ganfort showed 40% less hyperemia than bimatoprost monotherapy in clinical trials.

Bimatoprost is marketed by Allergan as Lumigan.